Related Experiment Videos
High-dose cyclophosphamide treatment for refractory severe aplastic anemia in children
Anthony N Audino1, Julie Blatt, Benjamin Carcamo
1Akron Children's Hospital, Akron, Ohio, USA.
Insights
High-dose cyclophosphamide shows promise for children with severe aplastic anemia (SAA) refractory to other treatments. Two of five pediatric patients achieved complete response, indicating potential efficacy in this challenging condition.
Area of Science:
- Pediatric Hematology
- Oncology
- Immunosuppressive Therapy
Background:
- Severe aplastic anemia (SAA) involves hematopoietic precursor depletion, leading to life-threatening complications.
- Hematopoietic stem cell transplant (HSCT) is preferred for SAA if an HLA-matched donor is available.
- Immunosuppression with anti-thymocyte globulin (ATG) and cyclosporine A (CSA) is an alternative, but high-dose cyclophosphamide use in pediatric SAA is limited.
Purpose of the Study:
- To evaluate the efficacy of high-dose cyclophosphamide in pediatric patients with refractory severe aplastic anemia (SAA).
Main Methods:
- Five pediatric patients with SAA, previously unresponsive to immunosuppressive therapy, received high-dose cyclophosphamide (45 mg/kg/day for 4 days).
Main Results:
- Two out of five patients achieved a complete response after 12 months of treatment.
- Complete responders demonstrated red cell and platelet recovery.
- One patient did not respond, and two patients died from infections.
Conclusions:
- High-dose cyclophosphamide can induce complete responses in pediatric SAA patients who have not responded to standard immunosuppressive treatments.
Objective:
To determine if high-dose cyclophosphamide is an effective therapy for children with refractory severe aplastic anemia (SAA).
Background:
SAA is an illness characterized by the depletion of hematopoietic precursors associated with life-threatening complications. Hematopoietic stem cell transplant (HSCT) is the treatment of choice if a human leukocyte antigen (HLA)-related donor is available. Immunosuppression with anti-thymocyte globulin (ATG) and cyclosporine A (CSA) is an option for patients who are not HSCT candidates. Unrelated donor HSCT has been used with limited success. High-dose cyclophosphamide has been used successfully in the treatment of adults with SAA, but experience in children is limited.
Procedure:
Five pediatric patients who had failed previous immunosuppressive therapy for SAA were treated with high-dose cyclophosphamide (45 mg/kg/day x 4 days).
Results:
After 12 months of treatment, two of five patients experienced a complete response with high-dose cyclophosphamide therapy. The two complete responders achieved red cell recovery with a hematocrit of >36% at days 212 and 112 and platelet recovery with a platelet count of >100 x 10(9)/L at days 126 and 324. Of the remaining patients, one patient failed to respond, and two patients expired from infectious complications.
Conclusions:
High-dose cyclophosphamide can lead to complete responses in children with SAA who have failed to respond to traditional immunosuppressive therapy.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Pharmacokinetics in Pediatric Patients: Drug Excretion